高流量治疗在长期氧疗中的效果 (HILOT)
高流量疗法在长期氧疗 (HILOT) 中的效果:一项多中心、基于注册的随机临床试验
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
研究概览
详细说明
This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.
The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Magnus Ekström, MD, PhD
- 电话号码:+46 0455731000
- 邮箱:magnus.ekstrom@med.lu.se
学习地点
-
-
-
Örebro、瑞典、70185
- 招聘中
- Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
-
接触:
- Josefin Sundh, MD, PhD
-
-
Blekinge County
-
Karlskrona、Blekinge County、瑞典、37185
- 招聘中
- Research Unit, Blekinge University of Technology
-
接触:
- Magnus Ekström, MD, PhD
- 邮箱:magnus.ekstrom@med.lu.se
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 40 years or older
- Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
- COPD or ILD as main underlying reason for LTOT
- Oxygen concentrator as stationary oxygen source in the home including night-time
- Body mass index (BMI) < 35 kg/m2
Exclusion Criteria:
- Current or previous treatment with home HFOT
- Current treatment with home mechanical ventilation
- Current treatment with home CPAP
- Hospitalized during the last 2 weeks
- Current smoking or contact with flames
- Self-reported average use of the LTOT < 15h per day (24 hours)
- PaCO2 (breathing air at rest) > 8 kPa
- Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
- Inability to participate in the study procedures (as judged by the staff)
- Not eligible for continuing LTOT due to other reason (as judged by the staff)
- Expected survival less than 3 months (as judged by the staff)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:High-flow oxygen therapy
Intervention arm |
Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time. |
|
有源比较器:Low-flow oxygen therapy
Comparison arm |
Standard care with low-flow oxygen therapy in accordance with clinical routine. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to first hospitalization or death from all causes
大体时间:1 year
|
Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data) |
1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to first all-cause hospitalization or all-cause death
大体时间:1 year
|
Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data) |
1 year
|
|
Rate of hospitalizations or death from all causes
大体时间:1 year
|
Rate of hospitalizations or death from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from all causes
大体时间:1 year
|
Hospitalization rate from all causes assessed using nationwide registry data |
1 year
|
|
Hospitalization rate from respiratory disease
大体时间:1 year
|
Hospitalization rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Number of hospitalized days
大体时间:1 year
|
Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data |
1 year
|
|
Hospitalization rate from cardiovascular disease
大体时间:1 year
|
Hospitalization rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Number of admissions to intensive care unit (ICU)
大体时间:1 year
|
Number of admissions to ICU assessed using nationwide registry data |
1 year
|
|
Number of days in ICU
大体时间:1 year
|
Number of days in ICU assessed using nationwide registry data |
1 year
|
|
Mortality rate from all causes
大体时间:1 year
|
The mortality rate from all causes assessed using nationwide registry data |
1 year
|
|
Mortality rate from respiratory disease
大体时间:1 year
|
The mortality rate from respiratory disease assessed using nationwide registry data |
1 year
|
|
Mortality rate from cardiovascular disease
大体时间:1 year
|
The mortality rate from cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Time to first exacerbation
大体时间:1 year
|
Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data |
1 year
|
|
Number of exacerbations
大体时间:1 year
|
Number of exacerbations of all severity assessed using self-reported and registry data |
1 year
|
|
Incidence of cardiovascular disease
大体时间:1 year
|
Incidence of cardiovascular disease assessed using nationwide registry data |
1 year
|
|
Need for home mechanical ventilation
大体时间:1 year
|
Need for starting home mechanical ventilation assessed using nationwide registry data |
1 year
|
|
Rate of withdrawal of long-term oxygen therapy
大体时间:1 year
|
Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data |
1 year
|
|
Adverse events
大体时间:3 and 12 months
|
Self-reported adverse events since study start assessed using a postal questionnaire. |
3 and 12 months
|
|
Primary care utilization
大体时间:1 year
|
Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire. |
1 year
|
|
Health-related quality of life
大体时间:3 and 12 months
|
Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire. |
3 and 12 months
|
|
Health status
大体时间:3 and 12 months
|
Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire. |
3 and 12 months
|
|
Breathlessness at exertion
大体时间:3 and 12 months
|
Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire. |
3 and 12 months
|
|
Breathlessness
大体时间:3 and 12 months
|
Self-reported breathlessness assessed using the Dyspnea-12 questionnaire. |
3 and 12 months
|
|
Sleep quality
大体时间:3 and 12 months
|
Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire. |
3 and 12 months
|
|
Physical activity
大体时间:3 and 12 months
|
Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire. |
3 and 12 months
|
|
Change in health status
大体时间:3 and 12 months
|
Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale. |
3 and 12 months
|
|
Nasal symptoms
大体时间:3 and 12 months
|
Self-reported nasal symptoms assessed using the modified Björklund questionnaire. |
3 and 12 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Patient preference for continuing the treatment
大体时间:3 and 12 months
|
Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire. |
3 and 12 months
|
合作者和调查者
合作者
调查人员
- 首席研究员:Magnus Ekström, MD, PhD、Skane University Hospital
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.